Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
Francesca Cainelli1, Alfredo Vallone21Department of Internal Medicine, School of Medicine, Faculty of Health Sciences, University of Botswana, Gaborone, Botswana; 2Infectious Diseases Unit, Annunziata Hospital, Cosenza, ItalyAbstract: Kaposi’s sarcoma is a vascular tumor linked to the...
Guardado en:
Autores principales: | Francesca Cainelli, Alfredo Vallone |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/6528d30976ad41b8be6093ae81e3766d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Viral and immunological markers of HIV-associated Kaposi sarcoma recurrence.
por: Owen Ngalamika, et al.
Publicado: (2021) -
Epidemiology of Kaposi’s Sarcoma
por: Sophie Grabar, et al.
Publicado: (2021) -
Disseminated Kaposi Sarcoma
por: Laura E. Goyack, et al.
Publicado: (2021) -
Pharmacokinetics, brain delivery, and efficacy in brain tumor-bearing mice of glutathione pegylated liposomal doxorubicin (2B3-101).
por: Pieter J Gaillard, et al.
Publicado: (2014) -
Higher efficacy and reduced adverse reactions in neoadjuvant chemotherapy for breast cancer by using pegylated liposomal doxorubicin compared with pirarubicin
por: Weifang Liu, et al.
Publicado: (2021)